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Gene expression from HIV-based gene therapy vectors or live-attenuated HIV-1 vaccines requires RNA transcription
supported by the HIV-1 promoter, the long terminal repeat (LTR). Delivery of live-attenuated HIV-1 vaccines as plasmid DNA
would overcome problems associated with production of attenuated HIV-1 strains. We investigated the expression of
reporter plasmids and proviral HIV-1 constructs driven by either the HIV-1 LTR or LTRs with deletions in the U3 enhancer
regions. LTR-driven plasmids were inoculated by gene gun into both human epidermis ex vivo and macaques in vivo. The
HIV-1 LTR drove reporter gene expression in human and macaque skin, although with 15- to 20-fold less efficiency compared
to the immediate-early cytomegalovirus promoter. A deleted LTR derived from a naturally attenuated HIV-1 strain infecting
a member of the well-characterized Sydney Blood Bank Cohort of long-term nonprogressors was 5-fold less efficient in
expression of the reporter gene compared to wild-type LTR. Delivery of proviral wild-type HIV-1 DNA constructs to human
skin resulted in recovery of HIV-1 from cells emigrating from the epidermis, providing an ex vivo model of the infectivity of
proviral HIV-1 DNA. However, delivery of proviral HIV-1 DNA containing deletions in either the LTR, Nef, or the secondary viral
transcription activator,Vpr, significantly reduced HIV-1 replication in this model. The early coexpression of Tat from a second
plasmid did not restore replication. Thus, although attenuated lentiviral vaccines might be deliverable as proviral DNA
constructs in primate subjects, significant improvements are needed to enhance the efficiency of this method. © 2001
Academic Press
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The HIV-1 pandemic continues to escalate, particularly
in less developed countries, and HIV vaccine research
remains a global priority. Among candidate HIV-1 vac-
cines that currently show promise are naked DNA vac-
cines expressing HIV-1 antigens and live-attenuated
HIV-1 vaccines (Barouch et al., 2000; Boyer et al., 1997;
Daniel et al., 1992).
HIV-1 DNA vaccines, by themselves, provide only par-
tial protection from AIDS-inducing viruses in animal mod-
els in comparison to live-attenuated lentiviral vaccines
(Barouch et al., 2000; Daniel et al., 1992; Lu et al., 1996).
Most DNA vaccines utilize the immediate-early cytomeg-
alovirus (CMV) promoter to drive antigen expression. The
CMV promoter is a strong, constitutive promoter in many
fibroblastoid tissue culture cells, but is comparatively
weak in T-lymphocytes that have not been activated with
mitogen and may have little advantage over the HIV-1
promoter, the long-terminal-repeat (LTR) (Hunninghake
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Microbiology and Immunology, University of
elbourne, Parkville, Victoria 3010, Australia. Fax: 61393471540. E-mail:
kent@unimelb.edu.au.71et al., 1989; Sambucetti et al., 1989). Indeed, the HIV-1
LTR might initiate more effective antigen expression in
important antigen-presenting cells such as macro-
phages or dendritic cells (Pope et al., 1994). Additionally,
since viral transcriptional transactivators such as Tat can
enhance the LTR promoter, codelivery of DNA vaccines
encoding Tat could increase LTR-driven gene expression
in primate tissues. In this study, we evaluated the effi-
ciency of gene-gun-delivered DNA vaccines and HIV-1
proviral DNA utilizing the LTR promoter in both ma-
caques and human skin.
Human subjects infected with HIV-1 strains attenuated
in vivo by the deletion of portions of the nef and LTR
genes or of vpr have been described (Alexander et al.,
2000; Deacon et al., 1995; Kirchhoff et al., 1995). The 12
individuals that constitute the Sydney Blood Bank Cohort
were infected by a common blood donor and have HIV-1
strains with a common deletion in the U3 region of the
LTR, in addition to various flanking deletions in nef and
U3, that account for the attenuated phenotype observed
(Deacon et al., 1995). Infection of macaques with nef/
LTR-deleted SIV provides protective immunity from viru-
lent SIV challenge (Daniel et al., 1992; Wyand et al., 1996).
owever, nef/LTR-deleted SIV and HIV-1 strains are only0042-6822/01 $35.00
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72 KENT ET AL.partially attenuated in vivo, resulting in disease in a
roportion of SIV-infected macaques and HIV-1-infected
umans (Baba et al., 1995; Learmont et al., 1999). Despite
hese limitations, should modified attenuated lentivirus
accines eventually prove both safe and efficacious, de-
ivering such viruses to large numbers of people in un-
eveloped countries poses logistical problems. Manu-
acturing difficulties involved in the production of live
entiviruses would be overcome if an infectious attenu-
ted HIV-1 vaccine could be manufactured as proviral
NA. A DNA-based vaccine would be inexpensive to
anufacture, quality control would be greatly simplified,
nd such a vaccine would resist degradation during
ransport. To date, examination of limited numbers of
noculated macaques suggests that wild-type SIV can be
elivered as proviral DNA intramuscularly (Letvin et al.,
991; Liska et al., 1999). However, delivery of nef/LTR-
eleted attenuated SIV or HIV-1 could be difficult since
he transcriptional efficiency of the LTR could be com-
romised as a result of deletions in the promoter and
nhancer regions. Although delivery of attenuated HIV-1
ould be practical when delivered as DNA, it may be
mportant to optimize this method of delivery. We com-
ared the efficiency of reporter gene expression by an
IV-1 LTR plasmid containing U3-region deletions to
ild-type HIV-1 LTR and CMV expression plasmids in
uman and macaque skin. In addition, we addressed
irectly the effect of deletions in LTR nef and vpr genes
n the levels of expression of HIV-1 in human skin ex-
lants after gene-gun transfection of HIV-1 provirus.
RESULTS
IV-1 LTR-mediated transcription in macaques in vivo
We compared the efficiency of LTR-mediated gene
xpression from DNA vaccines delivered to macaques
y gene gun, with or without the codelivery of Tat, to
ene expression mediated by the CMV immediate-early
IE) promoter commonly used by DNA vaccines. The
b-galactosidase (b-gal) reporter plasmids pCMVbgal,
pLTRNL4-3bgal, and pLTRNL4-3bgal plus pCMVtat, or
CMVtat control plasmid expressing only Tat, were ap-
lied to four limbs of two macaques by gene gun (Table
). Animals subsequently underwent skin biopsies at 2
ays and a regional lymph node biopsy at 14 days from
ll four limbs. Two days following immunization, b-gal
expression was readily observed by microscopy of
stained tissue sections of pCMVbgal-immunized skin
biopsies of both monkeys (Table 1, Figs. 2C and 2D).
b-gal-expressing cells were detected following gene-
gun delivery of the pLTRNL4-3bgal construct, but this
occurred with 15-fold less efficiency than the pCMVbgal
xpression. Codelivery of pCMVtat with the pLTRNL4-
bgal plasmid resulted in marginally (2- to 3-fold) more
b-gal expression than administration of pLTRNL4-3bgal
alone. HSince significant marker gene expression was observed
in the skin, draining lymph nodes from each immunized
limb were sampled at autopsy and examined for protein
expression 2 weeks after DNA inoculation. b-gal-positive
ells were observed in the lymph nodes draining limbs
eceiving b-gal immunization from both immunized ani-
als, but not in lymph nodes from the control limbs draining
he pCMVtat inoculated site. Lymph node cells positive for
b-gal were detectable but rare (3–10 cells) in the 10 histo-
logic sections screened from lymph node cells draining the
three sites of b-gal immunization (pCMVbgal, pLTRNL4-
bgal, and p LTRNL4-3bgal plus pCMVtat), without signifi-
ant differences between groups.
ild-type and attenuated LTR-mediated transcription
n human skin ex vivo
The efficiency of the HIV-1 LTR promoter in human skin
s not known. Additionally, it is not known whether plas-
ids bearing deletions in the U3 enhancer region of the
TR, such as those derived from the Sydney Blood Bank
ohort of long-term slow progressors, can mediate tran-
cription in primary human skin tissues. We delivered the
TR reporter constructs as DNA to human skin explant
ultures and subsequently assessed b-gal expression.
LTR NL4-3-driven plasmids expressed b-gal in a smaller
number of cells than the CMV IE promoter reporter plas-
mid by a factor of approximately 12 (Table 2). A deleted
LTR-driven reporter construct derived from a member of
the Sydney Blood Bank Cohort (pLTRC18mbcbgal) that
acks one of the GAGA elements of the negative regula-
ory element as well as the COUP, AP-1, NRT-1, Ets-1, and
ef-1 transcription factor binding elements resulted in
etectable gene expression (Table 2, Figs. 1, 2A, and 2B).
TABLE 1
In Vivo Expression in Macaque Skin of HIV-1 NL4-3 LTR or CMV IE
Promoter-Driven Reporter Constructs
Plasmid administered
(1 mg to skin
by gene gun)
Limb
administered
to
b-gal-expressing cells/
500 gold beads in
macaque skin biopsy 2
days after plasmid
inoculation
Monkey 1a Monkey 6a
pCMVtat Left arm 0, 0 0, 0*
pCMVbgal Right arm 82, 104 69, 43
pLTR NL4-3bgal Left leg 4, 6 3, 7
pLTR NL4-3bgal 1 Right leg 9, 15 12, 12
pCMVtat
a Two separate histologic sections from each biopsy were counted.
* There was a statistically significant difference in b-gal expression
ependent on the plasmid administered (P , 0.001, ANOVA). Individ-
al differences between pairs of the four groups were also all signifi-
ant (P , 0.01, Student’s t test).owever, pLTRC18mbcbgal detectable b-gal gene ex-
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73LTR EXPRESSION IN PRIMATE SKINpression was found in approximately fivefold fewer cells
in the human skin explants compared to the wild-type
HIV-1NL4-3 LTR reporter plasmid. Morphologically, the
vast majority of transfected cells in the epidermis were
keratinocytes utilizing either CMV or LTR promoters (Fig.
2B), and this was confirmed by flow cytometry of en-
hanced green fluorescent protein (EGFP)-transfected
epidermal cells (data not shown).
Expression of infectious virions in human skin ex vivo
after gene-gun transfection
The experiments utilizing the LTR-driven expression
constructs showed that wild-type LTR was 10- to 15-fold
more efficient at initiating gene expression in skin than
an HIV promoter bearing U3 deletions found in attenu-
ated HIV strains infecting the Sydney Blood Bank Cohort.
TABLE 2
Administration of Wild-Type and Deleted LTR Reporter Constructs
into Human Skin Explants
Plasmid
administered
b-gal-positive cells following 1 mg DNA injected
into 1 cm2 of human skin by gene guna
pCMVtat 0, 0, 0*
pCMVbgal 547, 782, 881
pLTRNL4-3bgal 39, 48, 92
LTRC18mbcbgal 6, 11, 15
a Three separate skin pieces were inoculated and counted for each
lasmid.
* There was a statistically significant difference in b-gal expression
ependent on the plasmid administered (P , 0.001, ANOVA). Individ-
al differences between pairs of the four groups were also all signifi-
ant (P , 0.04, Student’s t test).FIG. 1. Genetic sequence of the LTR (U3/R) component employed as b-We wished to test whether these LTR deletions and other
attenuating deletions in the nef and vpr genes would
iminish ongoing viral replication in the human skin
xplant model. To assess this, we expressed both T-cell
ropic (T-tropic, pNL4-3) and macrophage tropic
M-tropic, pNL(AD8)] proviral HIV-1 strains with deletions
n the vpr, nef, and/or U3 genes from proviral constructs
hat had a wild-type 59 LTR. The progeny virus from the
lasmid with a U3 deletion in the 39 LTR would transduce
he U3 deletion into the 59 LTR after the first infection
ycle. The two different env types were assessed since
revious studies utilizing live HIV-1 virus suggested that
-tropic strains more efficiently infected Langerhans
ells emigrating from human skin (Reece et al., 1998).
The previously described method for detecting HIV
roduction and transfer from the skin emigrants was
sed to determine HIV-1 replication after gene-gun trans-
ection (Reece et al., 1998). The epidermal cells emigrat-
ng from the epidermal sheets were cocultured with
ctivated PBMCs and reverse transcriptase (Fig. 3) and
CR (Fig. 4) assays for virus were employed. After trans-
ection of either the M-tropic pNL(AD8) or the T-tropic
NL4-3 molecular clones, HIV-1 replication was detected
n the cocultures by reverse transcription assays, with no
ignificant difference between the different strains with
ifferent tropisms (Fig. 3). The level of reverse transcrip-
ase activity in cocultures of cells migrating from epider-
is transfected with deleted provirus contructs was less
han in cocultures from skin transfected with wild-type
rovirus. Deletions in nef reduced virus production but
irus production was undetectable by reverse transcrip-
ase in cocultures where provirus defective in both nef
nd U3 or provirus with a vpr premature terminationgal reporter constructs of HIV-1C18mbc in comparison to HIV-1NL4-3.
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74 KENT ET AL.mutation was used. The more sensitive PCR assay
showed low levels of infection in cocultures following
transfection with proviral DNA containing the vpr muta-
ion, but not in cocultures following transfection with the
ef and U3 deletions (Fig. 4). The addition of pCMVtat by
otransfection together with the wild-type or deleted pro-
iral constructs did not increase or rescue HIV-1 replica-
ion (Fig. 3, right-hand panels, Fig. 4).
DISCUSSION
This study of HIV-1 LTR-mediated protein expression
n human and macaque skin found that 5- to 10-fold
ewer cells expressed b-gal under direction of the LTR
romoter compared to the CMV promoter in both human
nd macaque skin. In macaques, codelivery of HIV-1 tat
NA utilizing the CMV promoter resulted in a modest (2-
o 4-fold) increase in the number of cells expressing
b-gal from the LTR promoter in vivo. Both the CMV and
he LTR promoters resulted in small but detectable num-
ers of b-gal-positive cells in draining lymph nodes sam-
led 2 weeks after inoculation. The insignificant differ-
nces in lymph node expression seen between LTR and
FIG. 2. Expression of a marker gene in human and primate skin
following immunization with DNA using HIV-1 LTR promoter. A gene
gun delivered 1 mg of DNA attached to 1- to 3-mm gold beads into
human epidermal skin explants ex vivo (A and B) and monkey skin in
vivo (C and D). Expression of b-galactosidase protein was assessed by
X-gal staining of whole tissues. C was also stained with hematoxylin
and eosin to show epidermal tissues. The gold beads can been seen
as small dense particles within the epidermis and most b-galactosi-
ase-expressing cells contain one or more gold beads. The DNA
lasmids were as follows: (A) pLTRNL4-3bgal, (B) pLTRC18mbc-bgal (a
ell with morphology typical of a keratinocyte is shown), (C) pLTRNL4-
bgal, (D) pLTR NL4-3bgal 1 pCMVtat.MV-promoter expression may reflect the small numbersof transfected cells observed or differences in expres-
sion of these promoters in lymph node tissues (Leonard
et al., 1989). The finding of reporter gene expression in
lymph nodes has important implications for live-attenu-
ated HIV vaccines delivered as DNA to the skin, since
these viruses are likely to be required to reach the lymph
node to efficiently expand.
In human skin explants transfected with DNA ex vivo,
an LTR derived from a Sydney Blood Bank Cohort mem-
ber lacking a number of transcription factor binding ele-
ments resulted in approximately fivefold less efficient
gene expression compared to the wild-type LTR con-
struct. Use of the human skin explant model was con-
sistent with observations in macaque skin, suggesting
that this explant model could be used to assess the
relative efficiency of gene transfer and infectivity of HIV-1
in human skin in vivo. When human skin was transfected
ith a series of proviral HIV-1 DNA constructs, infectivity
f the skin emigrants was readily detectable from both
-tropic and M-tropic wild-type constructs. The deletion
f sequence within nef did not completely diminish viral
FIG. 3. Virus production in cocultures of activated T-cells and cells
emigrating from transfected skin explants. Skin was transfected with
M-tropic pNL(AD8) or T-tropic pNL4-3 proviral HIV-1 constructs or
pNL(AD8) constructs containing deletions in nef (pNL(AD8)Dnef2.1,
abeled -nef), deletions in nef plus U3 (pNL(AD8)DnefDU3, labeled -nef
U3), and a premature termination mutation in vpr (pNL(AD8)DR, la-
beled -vpr). Cells migrating from the epidermis were cocultured with
activated PBMCs and reverse transcriptase activity was monitored. The
kinetics of HIV-1 replication for each of four replicate transfections with
each construct is shown. The dashed line indicates the cutoff for a
negative value and is the mean 1 3 SD for cocultures of emigrants from
skin transfected with pCMVtat alone. The right-hand panels correspond
to the cultures from skin cotransfected with pCMVtat (1tat) and the
infectious clone indicated on the left.
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75LTR EXPRESSION IN PRIMATE SKINreplication in the cocultures; however, a termination mu-
tation in the vpr gene reduced replication such that it
as detected only by PCR, and a combined nef and U3
eletion completed abrogated infectivity of the proviral
ontruct in the skin explant model. The poor transfer of
ttenuated HIV-1 viruses from emigrating Langerhans
ells to stimulated PBMCs seen in this system is likely
he result of reduced production in the keratinocytes and
angerhans cells (LCs), reduced transfer from the trans-
ected keratinocytes to LCs, or reduced transfer from the
migrating LCs to the activated PBMCs.
Our results suggest that the protein expression levels
nd immunogenicity of DNA vaccines in either humans
r other primates are unlikely to be improved by utilizing
he LTR promoter, consistent with recently published
ata in macaque models (Galvin et al., 2000). The obser-
ation that the LTR-mediated gene expression in human
nd macaque tissues does occur is, however, consistent
ith reports of infections initiated in macaques by ad-
inistration of full-length wild-type proviral SIV DNA via
ntramuscular inoculation (Ilyinskii et al., 1997; Letvin et
l., 1991; Liska et al., 1999). Recent data suggest that
ild-type and LTR-deleted SIV infections can also be
nitiated by administering proviral SIV DNA to the skin
tilizing only 15 mg of DNA delivered epidermally via the
ene gun (S. Kent et al., unpublished data). Our results
here suggest that more efficient generation of lentiviral
infections could be mediated by generating constructs
using the heterologous CMV promoter in place of the 59
FIG. 4. PCR amplification of HIV-1 provirus in cocultures of T-cells
nd human skin emigrants. PCR for HIV-1 gag was performed on cells
arvested from day 16 of culture. Results for two skin samples are
hown for each plasmid construct. (A) Cocultures of skin transfected
ith M-tropic provirus pNL(AD8) and for T-tropic provirus pNL4-3. (B)
ocultures of skin transfected with pNL(AD8) with deletions of nef,
combined deletions of both nef and U3, and a premature termination
utation in vpr. Each set of transfections was also assessed following
he cotransfection of pCMVtat.LTR. Theoretically, the coadministration of Tat under the fcontrol of a CMV promoter could also enhance infectivity
of LTR-driven constructs, and a modestly higher propor-
tion of cells supported gene expression with coadminis-
tration of Tat (Table 1). However, no increase in infectivity
was observed when Tat was codelivered with deleted
proviral HIV-1 constructs to human skin (Figs. 3 and 4).
Coexpression of both tat and green fluorescent protein
(GFP) in the skin had no effect on the total number of LCs
emigrating from the epidermis or GFP-transfected LCs,
suggesting that tat was not having an effect on LC
viability or mobilization from the epidermis (data not
shown). The reduced infectivity following cotransfection
with tat could reflect competition between the CMV and
the LTR promoters or comparative inefficiency of Tat to
enhance replication of virus in the second round of viral
replication.
The observation that a deleted LTR derived from the
Sydney Blood Bank Cohort was less efficient than the
wild-type LTR suggests that the loss of critical transcrip-
tion factor binding elements may play a role in the atten-
uation of the infection observed in the Sydney Blood
Bank Cohort in addition to defects in Nef protein function
and stability. These observations on deleted LTRs in
human skin ex vivo are consistent with preliminary ob-
servations following transfection of immortalized cell
lines in vitro (P. Thompson et al., unpublished data) and
SIV-LTR studies (Ilyinskii et al., 1994, 1997; Ilyinskii and
Desrosiers, 1996; Pohlmann et al., 1998). Our results
suggest that utilizing proviral DNA may be an inefficient
way to deliver attenuated HIV-1 (or SIV) vaccines that
contain deletions in the LTR, especially in conjunction
with other deletions. Additional manipulations, such as
using the CMV promoter instead of the 59 LTR to drive the
initial round of virus production, may enhance the initial
replication from these deleted lentiviral constructs in
primary primate tissues and facilitate a more efficient
vaccination. Delivery of nef/LTR-deleted full-length SIV
plasmids as proviral DNA is now being assessed in
macaques in vivo.
MATERIALS AND METHODS
Plasmid constructs
The coding sequence for b-gal or the red-shifted EGFP
reporters was expressed from plasmids driven by the
CMV immediate-early promoter, the HIV-1NL4-3 LTR, or the
HIV-1C18mbc LTR (Adachi et al., 1986; Deacon et al., 1995).
he pEGFP-N1 plasmid expressing GFP from the CMV
romoter was purchased from Clontech (Palo Alto, CA).
he plasmid pCMVbgal was prepared by inserting
the b-gal coding fragment excised from pSVbgal with
HindIII to BamHI into the same sites of pEGFP-N1. The
pLTRNL4-3-EGFP plasmid was prepared by replacing the
AseI to HindIII fragment containing the CMV promoter
from pEGFP-N1 with the XhoI to HindIII 39 LTR fragment
rom the pNL4-3 proviral plasmid (Adachi et al., 1986).
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76 KENT ET AL.The plasmid pLTRNL4-3bgal was prepared by replacing
the HindIII to XbaI EGFP coding fragment of pLTRNL4-3-
EGFP with the HindIII to BamHI b-gal fragment from
pSVbgal. The pLTRC18mbc-EGFP and pLTRC18mbc-
bgal plasmids were prepared from the attenuated Syd-
ney Blood Bank Cohort virus, HIV-1C18mbc (GenBank Ac-
ession No. U37270), which contains deletions in the
egative regulatory element of the U3 region (Fig. 1)
Deacon et al., 1995). The HIV-1C18mbc LTR was amplified
y PCR using primers that included suitable restriction
ites and products cloned first into pCRII (Invitrogen, San
iego, CA) and then subcloned to replace the HIV-1NL4-3
LTR in the respective reporter plasmids.
HIV proviral plasmids included both pNL4-3 and pN-
L(AD8). pNL(AD8) replaces the KpnI to BsmI env frag-
ment of the CXCR4-tropic pNL4-3 with env from the
M-tropic ADA strain that uses the CCR5 coreceptor from
the pAD8.1 proviral clone (Englund et al., 1995; Freed and
artin, 1994; Theodore et al., 1996).
Proviral plasmids deleted by 267 bp in U3 (Fig. 1)
nd/or 222 bp in nef were first prepared in the NL4-3
ackground by removing the 59 BstEII site in the HIV-
NL4-3 39 half plasmids, p210-8 and p210-5 [(Gibbs et al.,
994), obtained from the AIDS Reference Reagent Pro-
ram (ARRP), Rockville, MD, 2486, 2485], by cutting with
coI and NruI, end-filling with Klenow, and religating the
lunt ends. The 59 half of HIV-1NL4-3 was added to the 39
half clones by purifying the BstEII and EcoRI fragment
rom p83-2 (ARRP 2497) and cloning this between the
ame sites in the 39 half plasmids. The M-tropic env was
ubstituted into these T-tropic clones by exchanging the
coRI to BamHI fragment from pNL(AD8), creating the
NL(AD8)Dnef2.1 and pNL(AD8)DnefDU3 plasmids. The
NL(AD8)DR plasmid has a premature termination in vpr
hat results from the frameshift resulting from the end-
illing and religation of the EcoRI site in the pNL(AD8)
lasmid.
Plasmid DNA was precipitated onto 0.95-mm gold
eads and delivered to shaved epidermis using a He-
riven Accell gene gun using 1 mg of DNA per shot as
reviously described (Kent et al., 1998). For the delivery
f both pCMVtat and pLTRNL4-3bgal, DNA was copre-
ipitated at 1 mg/shot for each plasmid onto the same
gold beads. Inoculations of both macaques and human
skin employed a He pressure of 350 psi.
Macaques
Two pigtailed macaques (Macaca nemestrina), M1
nd M6, were used previously for an HIV-1 infection
xperiment 12 months prior to the reporter DNA inocu-
ations described in this report (Kent et al., 1997). All
procedures were performed under ketamine anesthesia
and were approved by the Institutional Animal Ethics
Committee. The animals were immunized with 1 mg offour different preparations of DNA (pCMVtat. pCMVbgal,
pLTRNL4-3bgal, or pLTRNL4-3bgal 1 pCMVtat) attached
to gold beads to shaved skin of the four limbs (Table 1).
Two days later, the inoculated site was biopsied using a
5-mm punch skin biopsy. Fourteen days after immuniza-
tion, the animals were euthanized and the lymph node
most proximal to the immunization site of the draining
the axillary and inguinal lymph node groups was biop-
sied.
Human skin
Human skin was obtained with patient consent from
the Victoria Plastic Surgery Unit as normal skin other-
wise discarded at the time of breast reduction surgery.
Skin was stored at 4°C and processed within 2 h of
collection as previously described (Reece et al., 1998).
After incubation for 30 min on ice in RPMI medium
containing 250 mg/ml gentamicin (Durlock, Melbourne,
Victoria, Australia) the full-thickness skin was spread
on a sterile surface and transfected by a gene gun
(Helios, Bio-Rad) at a pressure of 350 psi. Split-thick-
ness skin was prepared from the transfected skin
using a Froud skin graft knife. Pieces of split-thickness
skin approximately 1 cm2 in surface area were placed
n culture in individual wells of a 6-well plate (Nunc,
aperville, IL) and cultured in RF10 consisting of RPMI
640 (PA Biologicals, Sydney, New South Wales, Aus-
ralia) supplemented with 10% heat-inactivated fetal
ovine serum (PA Biologicals), 20 mg/ml gentamicin,
10 mM HEPES (Trace Biologicals, Sydney, New South
Wales, Australia), and 2 mM glutamine (Trace Biologi-
cals).
Epidermal sheets were prepared from human skin
explants by culture at 4°C for 6 h in RPMI containing 5
mg/ml dispase (Worthington, Lakewood, NJ). After being
washed in PBS the epidermis was separated from the
dermis and processed for detection of b-gal.
b-Galactosidase expression in tissues
To assess comparative b-gal expression in tissues,
the skin or lymph nodes were fixed with 2% glutaralde-
hyde for 2 h, washed, and stained with X-gal (1 mg/ml,
Sigma), 5 mM potassium ferrocyanide, and ferricyanide
for 48 h at 37°C with shaking. Blue cells were counted
either by microscopy on separate histologic sections of
macaque skin or using an inverted microscope on the
entire 1-cm2 sheet of human epidermis. b-gal staining
was expressed as either the number of blue (transfected)
cells per 1 cm2 of skin that received 1 mg of DNA (human
skin) or, since the entire region of the gene-gun delivery
to macaque skin was not biopsied (a 5-mm punch biopsy
was taken), the number of blue cells/500 gold beads
counted (macaque skin).
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77LTR EXPRESSION IN PRIMATE SKINDetection of virus production from transfected skin
explants
Skin explants were transfected with plasmids coding
for HIV proviral constructs as described above. Split skin
from the site of transfection was prepared using the
Froud skin graft knife and then placed in culture in 6-well
plates overnight. Split skin sheets were dispase treated
as above and the epidermal sheets were placed in cul-
ture in 24-well plates. After a further day, 106 human
PBMCs previously activated with staphylococcal entero-
toxin B (40 ng/ml, Sigma) were added to each well to
expand any production of HIV-1. Epidermal skin sheets
were removed on day 3 and supernatants were har-
vested from day 4 through 16. Virus production was
determined by a reverse transcriptase assay described
previously (Reece et al., 1998) and modified to use a
hosphoImager (FLA 2000, Fuji Photo Film Co., Tokyo,
apan) to count incorporated radioisotope. On day 16,
ells were harvested and lysed, and PCR for HIV-1 was
arried out using the HIV-1gag-specific primers A2,
ggggacatcaagcagccatgcaaatg, and B2, actccctgacat-
ctgtcatcatttcttc (Reece et al., 1998).
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